Active Ingredient History
Denileukin diftitox was an antineoplastic agent, an engineered protein combining interleukin-2 and diphtheria toxin. Denileukin diftitox could bind to interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express these receptors, so denileukin diftitox can target these. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 1/Phase 2)
Breast Neoplasms, Male (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Ovarian Epithelial (Phase 2)
Colorectal Neoplasms (Phase 1)
Fallopian Tube Neoplasms (Phase 2)
Graft vs Host Disease (Phase 2)
Hamartoma (Phase 2)
Immune System Diseases (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lung Neoplasms (Phase 1)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell, Cutaneous (Phase 4)
Lymphoma, T-Cell, Peripheral (Phase 2)
Mastocytosis, Systemic (Phase 2)
Melanoma (Phase 2)
Multiple Myeloma (Phase 1)
Mycosis Fungoides (Phase 4)
Neoplasms (Phase 1)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Sezary Syndrome (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
